Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could short telomeres predict lung disease severity?

NCT ID NCT06885515

Knowledge-focused Sponsor: Barzilai Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether people with pulmonary fibrosis (a scarring lung disease) have shorter telomeres—the protective caps on the ends of chromosomes. Researchers will measure telomere length in blood samples from 100 Israeli patients and follow their health for two years. The goal is to understand how telomere length relates to disease progression, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify patients with short telomeres who may be at higher risk for worse outcomes, pointing toward more personalized monitoring or treatment approaches.
What could go wrong
This is an observational study, not a treatment trial. It will not directly test any new therapy, and the results may not lead to immediate changes in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A total of 90 patients with FILD will be recruited . This cohort will include 30 patients with familial pulmonary fibrosis and 60 with sporadic lung fibrosis. Patients with familial pulmonary fibrosis are those with at-least one first-degree or second-degree relative with FILD. 10 healthy age-matched controls with no personal or family history of lung disease will be recruited as controls.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult subjects, aged ≥18-years-old 2. Able and willing to provide informed consent to participate in the study 3. Lung fibrosis evident on chest CT (signs of honeycombing and/or traction bronchiectasis) \[17\] 4. Subjects fulfilling criteria 1 and 2 but with no evidence of chronic lung disease will serve as controls Exclusion Criteria: 1. Subjects with sarcoidosis as the etiology for FILD 2. Subjects who had undergone lung transplantation 3. Pregnant women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary fibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary fibrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Barzilai Medical Center

    Ashkelon, Israel

  • Tel Aviv Medical Center

    Tel Aviv, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.